Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PMCB Market Cap $49.68M. Overvalued by $49M. True value is cash on hand because they have nothing else of value unless issuing shares and PR's are considered an asset. IMHO!
"We are there" becomes "we’re almost there" LOL Shady Kenny. Nothing ever changes here except the date.
Another example of no news Pr's. PPS slipping below .05 so lets put out a PR about a test. No News on funding, CRO, IND timetable. If any real biotech released a PR everytime the completed a test they would be issuing PR's 50 times a day. Such a joke of a company. IMHO
It was almost as impressive as the TD2 video. Oh ya TD2 dumped PMCB after they realized they were only about PR's not medicine.
The company is a typical penny stock scam. Hook people into thinking that a penny stock company like PMCB has a revolutionary treatment for Cancer through hundreds of PR's and email blasts then get them to buy even more after the initial PPS jump to average down and then get them to be afraid if they sell they could be missing out on $RICHES$. When in fact its all about the management getting paid and selling even more shares. Almost 6 years of the complete nonsense and what have they accomplished? A cell bank. Why do you think TD2 walked away after a couple of years. TD2 realized they were only being used for their name and that PMCB was never going to trial. IMHO
Same prediction every week from the same people. News next week, don't get caught chasing, .20-.50 in a couple weeks. What news is coming next week? Shady Kenny hired another do nothing Director. Shady Kenny hired another Hollywood Agent. Pmcb agrees to give Austrianova more money so they don't go under. PMCB completed another test that they claimed was completed 5 years ago. Maybe Stock Market Media will conduct another paid PR posing as an interview. Its a scam and it always has been. IMHO
Almost as good as the TD2 pictures. Oh ya that didn't end well.
Six years of "we are there" and clinical trials soon. All a means to enrich Shady Kenny and his crooked buddies. Six years of selling hundreds of millions of shares at huge discounts to friends who are basically laundering shares to individual shareholders with fairy tale PR's of a treatment that not one real Biotech wanted. 2013,2014,2015,2016,2017 and 2018 "soon" we are there" Hundreds if not thousands of Paid for PR's. 2019 here we come...... IMHO!
PMCB PPS 9/22/2008 .05 9/20/2018 .05. Ten years of dead money for the long time holders yet many still try day after day to convince others that they have a lifetime opportunity stock. The lifetime opportunity was for Shady Kenny and his band of thieves who have sucked Tens of Millions of $$ into their bank accounts. IMHO
Amazing facts! LOL !! Fact is dumping shares is a plus plus for Kenny and his shady pals. Dump shares at 67% discount to "friends" who sell back into the market at a huge profit on PMCB pump staged interviews. Shady Kenny gets paid friends get paid. Fund operations LOL. What operations? IMHO
A $50,000,000 is not undervalued for a company with no progress in 6 years, no cash, no ability to raise cash other then to pay Shady management and a 20+ year old technology whose only clinical trials are not recognized by the FDA as having any meaning. 1.1 BILLION shares outstanding and no cash on hand yet somehow the claim is they are going to conduct a trial that will cost $20,000,000 of which just the startup costs (IND cost,CRO cost,Site prep, etc.) will be around $8-$10 Million. Selling shares at .02 they would need to sell another BILLION shares.
Warning Signs for OTC Companies. SOUNDS LIKE PMCB
In observing a great number of OTC company failures, we have noted the following patterns followed by many OTC companies that fail:
The company is usually recently founded through the name changed accordingly to address a particular exciting disruptive technology such as 3D Printing, Nano Drug Delivery, Graphene, Solar, etc.)
The company possesses one patent or a small number of patents that are said to address an application of said disruptive technology. These patents will usually be acquired in the reverse merger or invented by someone in senior management whose credentials and past successes are heavily touted.
The company’s marketing materials, financial statements, SEC filings, etc will expand upon in great detail the size of the market opportunity and just how exciting of an opportunity exists as opposed to the success of their product in capturing revenue from said market application.
Many individuals on stock message boards such as the ones found on Yahoo Finance will suddenly start posting messages touting the merits of the stock using phrases such as “load up”, “get on the train”, “the next Microsoft”, “easy ten bagger”, etc.
Any constructive criticism of the company will be met with accusations of short selling when in fact the short selling of OTC stocks is very difficult and rare
In addition to the original technology focus, the company will then start to identify other application opportunities for their technology when the original opportunity does not transpire
They will then continue issuing private placements to support the company until the share price completely collapses and the long term shareholders are left holding shares that are worthless
It is important to note that senior management of the company are paid whether or not the company succeeds.
Kenneth L Waggoner #58550
http://members.calbar.ca.gov/fal/Licensee/Detail/58550
License Status: Active
Address: Pharmacyte Biotech, Inc., 23046 Avenida De La Carlota, Ste 600, Laguna Hills, CA 92653-1537
County: Orange County
Phone Number: (917) 595-2850
Fax Number: (917) 595-2851
Email: kwaggoner@PharmaCyte.com
Law School: Loyola Law School; Los Angeles CA
PMCB IR gave out a shareholders name to another shareholder. How unprofessional can this company get.
Not one piece of real information in that email. Always deflecting the blame on others. Lots of traveling where on Vacation. LOL just like i posted earlier PMCB tells everyone nothing and some cheer. IMHO
it will be as easy as 1234jklm to post.
As soon as PMCB issues another PR most here will be right back in the cheering section. Doesn't matter if its the same old BS. The fact is many just want PR's not real news or progress or they would have been pressuring the Shady management of this fake Biotech years ago instead of cheering their every non-news press releases. Fact is other then having a vendor grow a cell bank this company has accomplished NOTHING since Shady Kenny took over. IMHO
What did you all expect. Shady Kenny is a corporate lawyer and not a very good one considering the only Job he has had the past 15 years is in penny stock companies. He has ZERO experience in running a Biotech. He is 70 years old and not exactly working 12 hour days (or it appears any hour days) Crabtree is basically retired as his salary going down the past two years clearly shows and he is 80 YEARS OLD and hasn't worked for a real biotech in decades. Other then these two the only other actual employee is a CPO buddy of KW that contributes nothing. Every other person PMCB claims to be working hard has a full time ++ job and spends ZERO hours a day on CIAB. The company has no Cash and no means to raise cash for anything other then paying its do nothing Management. Like i said many times before PMCB is a stock selling company that only releases silly PR's when they need to help whoever is buying shares at .02 sell them to people that are fooled into believing that "Trials are starting soon". SIX years they have been sell this BS!!! IMHO
When a company sells 66,239,316 (6.4% of outstanding shares) shares at 2.3 cents (67% Discount)just before it releases a bunch of PR's (we are there, Cells shipped etc... )and no one ever reports owning these shares its because they sold into the PR's at 300-400% profit. The the company goes silent until it needs to raise more money to pay its shady management. So don't worry more useless PR's are coming soon because cash is running low. IMHO
From May 1, 2018 through July 20, 2018, the Company sold 66,239,316 shares of common stock using the Second S-3 structured as a Block Trade. The issuance of these shares resulted in gross proceeds to the Company of approximately $1,500,000. Pursuant to the Aeon Agreement, the Company is required to pay Aeon a fee of 7%, $105,000 and provide warrant coverage of 5% of the number of shares of commons stock sold in the Block Trade with a five-year term of approximately 3.3 million warrant shares.
What new Investor would even consider a company that can't even update their website.
Subject to FDA approval, we plan to commence a clinical trial in 2017. The trial is designed to show that our Cell-in-a-Box® plus low-dose ifosfamide therapy can serve as an effective and safe consolidation chemotherapy for patients whose tumors no longer respond after four to six months of therapy with Abraxane® plus gemcitabine. The trial will take place in the U.S. with study sites in Europe. Translational Drug Development (“TD2”) will conduct the trial in the U.S. Clinical Network Services (“CNS”) will conduct the trial in Europe in alliance with TD2. TD2 will be responsible for clinical development plans, program analysis, medical writing, clinical management and database development.
And who would even consider investing in a company run by a known Scam Artist like Kenny Waggoner. A Hack corporate lawyer running a pretend Biotech after running a scam Telcom (Chinatel) IMHO
Here is who everyone should be emailing. The Shady King of PMCB.
kwaggoner@PharmaCyte.com
Kenneth L Waggoner #58550
License Status: Active
Address: Pharmacyte Biotech, Inc., 23046 Avenida De La Carlota, Ste 600, Laguna Hills, CA 92653-1537
County: Orange County
Phone Number: (917) 595-2850
Fax Number: (917) 595-2851
Email: kwaggoner@PharmaCyte.com
Law School: Loyola Law School; Los Angeles CA
46,375,000 and didn't pay for one of them with his own money.
PPCB is running the same scam as PMCB. Notice they hired the same scam man Alan Morell as Senior Strategic Advisor. They have been telling everyone for years just like PMCB that they will be in trials "soon". Just another pretend biotech.
No real Institutional investors. Lets not play the pretend game
Institutional Ownership 00.15%. Lots?? LOL
Decreased Positions (2) 504,528
Held Positions (3) 1,073,017
Total Institutional Shares (5) 1,577,545
LOL been getting close for 6 years now. When you have a company that has no real Institutional investors and only raises enough capital (at 67% discounts) to pay its Shady Management. No Insider buying ever by anyone involved with PMCB. No office or research space and no regulatory personnel no coverage by any real media other then the paid for articles written by PMCB. No regular shareholder updates. No CRO and no money to pay the IND fee never mind actual clinical trials. I am pretty sure you have a SCAM IMHO.
Another day, Another week, Another Month, and soon Another Year of nothing from PMCB. Six + Years since acquiring the rights to CIAB and what are the accomplishments? PMCB had a vendor create a MCB. Management sure earned the TENS OF MILLIONS $$ they have paid themselves. PMCB is a SCAM IMHO
The same thing he said in every press release for every company he collects a paycheck from. I don't blame these Doctors for taking money from wherever they can I blame the companies like PMCB for using their Names as a way to sell shares. Do you know how many companies Von Hoff is associated with because he makes Hidalgo look like a rookie. IMHO of course!!
Here are all the companies Dr. Hidalgo is associated with not to mention his FULL TIME JOB. Lets not pretend he spends one minute a day thinking about PMCB unless its to collect his advisors paycheck.
Dr. Manuel Hidalgo, M.D., Ph.D., serves as a Scientific Advisor of Champions Oncology, Inc. Dr. Hidalgo serves as a Director of Oncology for the Centro Nacional de Investigaciones Oncológicas (National Cancer Institute of Spain). Dr. Hidalgo served as an Advisor of Cavion LLC (formerly, Tau Therapeutics LLC) until August 17, 2017 and also served as its Scientific Advisor. He served as Scientific Advisor of Champions Biotechnology, Inc. from June 11, 2007 to April 2008 and served as its Chief Scientific Officer since March 2008. He has been a Member of Medical and Scientific Advisory Board at PharmaCyte Biotech, Inc. since July 2015. He serves as a Member of OncoAssist Advisory Board at MedTrust Online LLC. He serves as a Member of Scientific Advisory Board at VCN Biosciences SL and Oncomatryx Biopharma, S.A. He serves as a Member of the Scientific Board of Targeted Molecular Diagnostics LLC. He serves as a Director of Centro Integral Oncologia “Clara Campal“ in Madrid, Spain. He serves as a Member of Scientific Advisory Board at Sun BioPharma, Inc. He served as a Member of the Scientific Advisory Board of Aclara Biosciences Inc. since October 2004. He served as a Director of Champions Biotechnology Inc. from June 11, 2007 to April 2008. Dr. Hidalgo served as a Member of Scientific Advisory Board of Monogram Biosciences Inc. (formerly, Virologic Inc). He is European Strategy Consultant. In 1997, he began his career as a clinical research fellow at the Cancer Therapy and Research Center in San Antonio, Texas, where he participated in the EORTC/NCI Exchange Fellowship and AACR Young Investigator Fellowship in Clinical Research. He serves as an Editorial Board of the Journal of Clinical Oncology and Clinical Cancer Research and is a Senior Editor for Molecular Cancer Therapeutics. He is a co-founder and Chairman of the international Pancreatic Cancer Research Team and is also a member of the NCI Developmental Therapeutics Study. He serves as an Associate Professor of Oncology and Co-Director of the Drug Development Program at Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine in Baltimore, Maryland. Dr. Hidalgo is considered a leading researcher in the development of targeted therapies for the treatment of cancer in patients with solid tumors. Dr. Hidalgo is the Principal Investigator in four new clinical studies started within the last year at the Drug Development Program at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine. He worked as both an Assistant Professor of Medicine at University of Texas Health Science Center and as a clinical investigator at the Cancer Therapy and Research Center. He has published more than 220 papers in peer-reviewed journals. His work has been funded by numerous sources, including the National Cancer Institute, the National Institutes of Health, the American Association for Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO). He obtained the ASCO Career Development Award in 2001. He is a Member of Scientific Advisory Board of KAHR medical Ltd. Dr. Hidalgo is one of Europe’s leading clinical and laboratory investigators in the field of pancreatic cancer. He trained at MD Anderson Cancer Center and was a faculty member. Dr. Hidalgo’s clinical trials group focuses on novel therapeutics for pancreatic cancer. He has participated in the clinical development of more than 30 novel anticancer agents and many major pancreatic cancer studies including the Abraxane® studies. He led the early clinical trials with erlotinib and temsirolimus - two approved drugs. Dr. Hidalgo pioneered the utilization of personalized xenograft models for drug screening, biomarker development and personalized cancer treatment. His research focuses on optimizing the clinical development of novel treatments by measuring target receptor and molecular anomalies, as well as analyzing the biological activity in tumor and normal tissues of patients treated with specific therapies. Dr. Hidalgo is also the author of a recent New England Journal of Medicine review of pancreatic cancer treatment. He received an AACR Clinical Research Fellowship and an ASCO Career Development Award for his work on the development of EGFR inhibitors. His efforts focus on novel therapeutics for pancreatic cancer. He specialized in Medical Oncology at the University Hospital “12 de Octubre” in Madrid where he obtained his license in 1996. He completed his training in drug development at the University of Texas Health Science Center, San Antonio. Dr. Hidalgo received his Medical Degree (M.D.) from University Navarra Medical School in Pamplona, Spain and his Ph.D. in Infectious Diseases in Cancer from University of Autonoma in Madrid, Spain
No Insider Buying Ever.
A company that some here claim to have a revolutionary treatment to cure every disease known to man yet not one Insider has ever purchased a single share to help fund development. All of the so called Greatest in the world consultants and not one has invested a single dollar to advance this technology. In fact all of them take lots of money and free shares by having PMCB sell shares at .02 (67% discount). Is the technology any good? I don't see anyone involved with it putting their own money on the line to prove it. As a matter of fact i haven't seen anything happen with it for 20+ years. IMHO
Wrong again you forgot the word locally
Twenty-five percent of patients with pancreatic cancer present with locally advanced disease that is unresectable,
So Shady Kenny says they have nothing to do but wait on vendors and PMCB investor relations says they are to busy to write a detailed update for investors. What exactly does the Shady one do all day? My guess would be he is double dipping doing legal work for clients while being paid by PMCB.
Its silly how some still believe this is a real company. IMHO
Well was this a lie?
10 APR 14
Nuvilex Engages ViruSure to Establish Cell Banks for Phase 2b Clinical Trials in Pancreatic Cancer
Or this?
27 MAR 15
today announced that the genetically modified cells that are required for its three planned clinical trials have been fully tested and are in the process of being propagated to produce all of the cells necessary for the clinical trials.
Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte Biotech, stated, “We are very pleased that work being done to grow the cells required for our clinical trials has proceeded according to our plans. Together with our partner, Austrianova, we are complying with all current regulatory guidelines to ensure that these cells will be made available to us as quickly as possible so we can commence our clinical trials in a timely fashion.”
How about this?
19 MAY 15
Q: What other milestones do you hope to accomplish in 2015?
Initiation of the Phase 2b clinical trial in Australia in patients with advanced pancreatic cancer. This is expected to begin in late 3Q2015.
2. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment dealing with pain associated with advanced pancreatic cancer. This trial, to be conducted in the U.S., is expected to begin in late 3Q2015.
3. Initiation of the Phase 1/2 clinical trial on the effectiveness of PharmaCyte’s pancreatic cancer treatment in slowing the accumulation of malignant ascites fluid. This trial, to also be conducted in the U.S., is expected to occur in late 3Q2015 or early 4Q2015.
Maybe this?
04 JAN 16
2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial
PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, stated, “We are excited to see 2016 arrive as this is the year that we will get into the clinic with our pancreatic cancer treatment. Our shareholders should understand that nothing whatsoever will deter our efforts to get into the clinic and to showcase our novel treatment for pancreatic cancer.”
An Investigational New Drug Application (IND) will be filed with the FDA following a pre-IND meeting with the FDA.
PharmaCyte’s clinical trial in pancreatic cancer will get underway with Translational Drug Development (TD2) coordinating the trial globally and conducting it in the United States. Clinical Network Services (CNS) will conduct the trial in Europe and Australia in alliance with TD2.
PharmaCyte will hold an annual shareholder meeting.
LOL Keep drinking the Kool Aid while Kenny boy fills his bank account.
Every day same old BS conspiracy stuff. PMCB is never to blame are they. Its:
Big Pharma
MM's
Vendors.
Paid Bashers
Shorts
Traders
Blah Blah
PMCB is a fake biotech run by a shady lawyer a washed up old doctor and a CPA. Their only purpose the past 7 years is to sell shares so the can pay themselves Millions of dollars and fade off into retirement. Some day you will realize this. IMHO
All the money that could have been made over the past many many years by people that were fooled into believing PMCB is a real Biotech. All of the lies told by Shady Kenny that have kept those peoples money locked into a Scam penny stock company while the stock market has soared. The Tens of $$Millions in unearned pay given to these frauds. The technology is great? How would anyone know its all just theory and has proven nothing because right now its just being used as a tool to legally steal money. Issue PR's, Sell stock and pay Old Shady do nothing management.
PMCB is a stock selling company. Plain and simple. They sell tens of millions of shares to a friendly third party at .02 so Kenny and his shady crew can collect $ Millions $ then they release paid promotion like the stock market media interview a couple months ago to get people to by those shares at 3-4 times the price paid thinking something big is going to happen. Then silence until the cycle needs to repeat. Year after year. A 70 year old lawyer and a 80 year old washed up doctor and Kenny CPA buddy collecting $ MILLIONS $ and doing NOTHING. Buyer be VERY AWARE. Go to PMCB's own website and read their years of empty promises in their news feed. IMHO
Its hysterical how some go back and quote from company updates as if they mean anything real. This POS company has never ever been truthful when it comes to releasing updates. Not a single milestone ever hit and never any verifiable information ever released. Its all a big fairy tale made up to enrich management and their shady friends. PMCB is a penny stock scam do your homework, read all of the BS released over the years on PMCB's own website. IMHO
PMCB will send Austrianova more cash so they can keep the scam alive. Ammendment to the ammendment PMCB has agreed to pay Austrianova $150k per month to retain the right of refusal to their treatment no one else wants but it will allow us to continue to sell millions and millions of shares and pay ourselves millions and millions of dollars.
Its been coming for almost a decade now. The fictitious clinical trial after the fictitious IND run by the fictitious CRO and paid for with Kenny bucks.
If your a true believer good for you and keep dreaming of your fictitious profits. If your a new investor ask yourself how a penny stock company with no money, no CRO and no regulatory or research employees that has been lying about starting a clinical trial for 8 years is actually a real biotech. A penny stock lawyer and his accountant buddy with NO physical location other then a rented closet that spends all of its cash raised by selling shares at 66% discounts paying themselves is a bio-scam.
Phamacyte, Nuvilex, Efood saftey. The name may change every few years but the SCAM remains. IMHO